{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T22:36:43Z","timestamp":1769726203460,"version":"3.49.0"},"reference-count":53,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,2,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>We previously found that the novel VR23 proteasome inhibitor not only possesses an effective antitumor activity without causing any ill effects to animals but also reduces side effects caused by a partner drug when used in combination. In this article, we report that VR23, unlike other proteasome inhibitors, exhibits potent anti-inflammatory activity. In the LPS-induced THP-1 monocyte model, VR23 downregulates proinflammatory cytokines IL-1\u03b2, TNF-\u03b1, IL-6, and IL-8 at a similar efficacy to dexamethasone. In contrast, two well-known proteasome inhibitors, bortezomib and carfilzomib, do not effectively downregulate these proinflammatory cytokines. Data from a study with SW982 synovial cell line and primary human synoviocytes showed that VR23 not only effectively downregulates IL-6 but also inhibits cell migration. Interestingly, the IL-6 downregulation by VR23 was significantly more pronounced in the primary synovial cells from rheumatoid arthritis patients than those from healthy donors, suggesting that VR23 can be selective against rheumatoid arthritis. Finally, VR23 effectively reduces neutrophil migration, TNF-\u03b1 secretion, and tissue inflammation in mice (female BALB\/c strain) with an LPS-induced acute lung injury. Thus, our current data indicate that VR23 can be effective on both acute and chronic inflammatory conditions. Taken together with our previous work, VR23 is not only effective on inflammatory conditions but also applicable to different aspects of cancer control, including the treatment and prevention of tumor development by chronic inflammatory responses.<\/jats:p>","DOI":"10.4049\/jimmunol.1900531","type":"journal-article","created":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T20:25:11Z","timestamp":1578515111000},"page":"788-795","source":"Crossref","is-referenced-by-count":8,"title":["The VR23 Antitumor Compound Also Shows Strong Anti-Inflammatory Effects in a Human Rheumatoid Arthritis Cell Model and Acute Lung Inflammation in Mice"],"prefix":"10.1093","volume":"204","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7959-0044","authenticated-orcid":false,"given":"Amanda","family":"Durkin","sequence":"first","affiliation":[{"name":"Health Sciences North Research Institute , Sudbury, Ontario P3E 2H3 ,","place":["Canada"]},{"name":"Biomolecular Sciences Program, Laurentian University , Sudbury, Ontario P3E 2C6 ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5802-0931","authenticated-orcid":false,"given":"Hai-Yen","family":"Vu","sequence":"additional","affiliation":[{"name":"Health Sciences North Research Institute , Sudbury, Ontario P3E 2H3 ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hoyun","family":"Lee","sequence":"additional","affiliation":[{"name":"Health Sciences North Research Institute , Sudbury, Ontario P3E 2H3 ,","place":["Canada"]},{"name":"Biomolecular Sciences Program, Laurentian University , Sudbury, Ontario P3E 2C6 ,","place":["Canada"]},{"name":"Department of Medicine, Faculty of Medicine, University of Ottawa , Ottawa, Ontario K1H 5M8 ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,2,15]]},"reference":[{"key":"2025030417510723900_r1","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1158\/1940-6207.CAPR-16-0209","article-title":"Targeting inflammation in cancer prevention and therapy","volume":"9","author":"Todoric","year":"2016","journal-title":"Cancer Prev. Res. (Phila.)"},{"key":"2025030417510723900_r2","first-page":"854","article-title":"Nitric oxide and oxygen radicals in infection, inflammation, and cancer","volume":"63","author":"Maeda","year":"1998","journal-title":"Biochemistry (Mosc.)"},{"key":"2025030417510723900_r3","doi-asserted-by":"crossref","first-page":"14007","DOI":"10.1073\/pnas.1211509109","article-title":"Chronic epithelial NF-\u03baB activation accelerates APC loss and intestinal tumor initiation through iNOS up-regulation","volume":"109","author":"Shaked","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2025030417510723900_r4","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nature01322","article-title":"Inflammation and cancer","volume":"420","author":"Coussens","year":"2002","journal-title":"Nature"},{"key":"2025030417510723900_r5","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/BF02944348","article-title":"Non-steroidal anti-inflammatory drugs (NSAIDs) and gastro-intestinal toxicity: current issues","volume":"168","author":"Shah","year":"1999","journal-title":"Ir. J. Med. Sci."},{"key":"2025030417510723900_r6","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0140-6736(13)60900-9","article-title":"Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials","volume":"382","author":"Bhala","year":"2013","journal-title":"Lancet"},{"key":"2025030417510723900_r7","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1161\/CIRCULATIONAHA.106.181424","article-title":"Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American heart association","volume":"115","author":"Antman","year":"2007","journal-title":"Circulation"},{"key":"2025030417510723900_r8","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1042\/cs0940557","article-title":"Anti-inflammatory actions of glucocorticoids: molecular mechanisms","volume":"94","author":"Barnes","year":"1998","journal-title":"Clin. Sci. (Lond.)"},{"key":"2025030417510723900_r9","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1365-4632.2009.04322.x","article-title":"Prevention and treatment of systemic glucocorticoid side effects","volume":"49","author":"Moghadam-Kia","year":"2010","journal-title":"Int. J. Dermatol."},{"key":"2025030417510723900_r10","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/s12098-008-0211-6","article-title":"Strategies for minimizing corticosteroid toxicity: a review","volume":"75","author":"Aulakh","year":"2008","journal-title":"Indian J. Pediatr."},{"key":"2025030417510723900_r11","first-page":"1","volume-title":"Report to Congress.","author":"The Autoimmune Diseases Coordinating Committee","year":"2005"},{"key":"2025030417510723900_r12","author":"National Institute of Allergy and Infectious Diseases","year":"2015","journal-title":"Autoimmune Dis"},{"key":"2025030417510723900_r13","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/nature01661","article-title":"Evolving concepts of rheumatoid arthritis","volume":"423","author":"Firestein","year":"2003","journal-title":"Nature"},{"key":"2025030417510723900_r14","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.2146\/ajhp050514","article-title":"Treatment of rheumatoid arthritis","volume":"63","author":"Gaffo","year":"2006","journal-title":"Am. J. Health Syst. Pharm."},{"key":"2025030417510723900_r15","doi-asserted-by":"crossref","first-page":"406","DOI":"10.7326\/0003-4819-146-6-200703200-00005","article-title":"Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial","volume":"146","author":"Goekoop-Ruiterman","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"2025030417510723900_r16","doi-asserted-by":"crossref","first-page":"4164","DOI":"10.1158\/0008-5472.CAN-14-3370","article-title":"VR23: a quinoline-sulfonyl hybrid proteasome inhibitor that selectively kills cancer via cyclin E-mediated centrosome amplification","volume":"75","author":"Pundir","year":"2015","journal-title":"Cancer Res."},{"key":"2025030417510723900_r17","doi-asserted-by":"crossref","first-page":"6315","DOI":"10.1038\/s41598-019-42816-4","article-title":"Examination of novel 4-aminoquinoline derivatives designed and synthesized by a hybrid pharmacophore approach to enhance their anticancer activities","volume":"9","author":"Solomon","year":"2019","journal-title":"Sci. Rep."},{"key":"2025030417510723900_r18","first-page":"847373","article-title":"Proteasome inhibitor bortezomib suppresses nuclear factor-kappa B activation and ameliorates eye inflammation in experimental autoimmune uveitis","volume-title":"Mediators Inflamm.","author":"Hsu","year":"2015"},{"key":"2025030417510723900_r19","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2174\/156800911794519752","article-title":"Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives","volume":"11","author":"Chen","year":"2011","journal-title":"Curr. Cancer Drug Targets"},{"key":"2025030417510723900_r20","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1167\/iovs.12-9505","article-title":"Anti-inflammatory effect of the proteasome inhibitor bortezomib on endotoxin-induced uveitis in rats","volume":"53","author":"Chen","year":"2012","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"2025030417510723900_r21","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1182\/blood-2009-01-199604","article-title":"Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells","volume":"114","author":"Hideshima","year":"2009","journal-title":"Blood"},{"key":"2025030417510723900_r22","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/path.4723","article-title":"Bortezomib-induced pro-inflammatory macrophages as a potential factor limiting anti-tumour efficacy","volume":"239","author":"Beyar-Katz","year":"2016","journal-title":"J. Pathol."},{"key":"2025030417510723900_r23","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.cellimm.2012.09.007","article-title":"Impairment of lysosomal functions by azithromycin and chloroquine contributes to anti-inflammatory phenotype","volume":"279","author":"Nuji\u0107","year":"2012","journal-title":"Cell. Immunol."},{"key":"2025030417510723900_r24","first-page":"82","volume-title":"Semin. Arthritis Rheum.","author":"Fox","year":"1993"},{"key":"2025030417510723900_r25","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1080\/14740338.2017.1269168","article-title":"Hydroxychloroquine in systemic lupus erythematosus (SLE)","volume":"16","author":"Ponticelli","year":"2017","journal-title":"Expert Opin. Drug Saf."},{"key":"2025030417510723900_r26","first-page":"365","volume-title":"Arthritis Research.","author":"Rosengren","year":"2007"},{"key":"2025030417510723900_r27","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1093\/jnci\/82.13.1107","article-title":"New colorimetric cytotoxicity assay for anticancer-drug screening","volume":"82","author":"Skehan","year":"1990","journal-title":"J. Natl. Cancer Inst."},{"key":"2025030417510723900_r28","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1038\/nprot.2006.179","article-title":"Sulforhodamine B colorimetric assay for cytotoxicity screening","volume":"1","author":"Vichai","year":"2006","journal-title":"Nat. Protoc."},{"key":"2025030417510723900_r29","doi-asserted-by":"crossref","first-page":"7888","DOI":"10.1016\/j.bmc.2008.07.076","article-title":"The efficacy and selectivity of tumor cell killing by Akt inhibitors are substantially increased by chloroquine","volume":"16","author":"Hu","year":"2008","journal-title":"Bioorg. Med. Chem."},{"key":"2025030417510723900_r30","doi-asserted-by":"crossref","DOI":"10.3791\/51046-v","article-title":"In vitro cell migration and invasion assays","author":"Justus","year":"2014","journal-title":"J. Vis. Exp."},{"key":"2025030417510723900_r31","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1007\/s10753-014-9858-5","article-title":"Anti-inflammatory effects of triptolide in LPS-induced acute lung injury in mice","volume":"37","author":"Wei","year":"2014","journal-title":"Inflammation"},{"key":"2025030417510723900_r32","first-page":"117","article-title":"Validity of SW982 synovial cell line for studying the drugs against rheumatoid arthritis in fluvastatin-induced apoptosis signaling model","volume":"139","author":"Chang","year":"2014","journal-title":"Indian J. Med. Res."},{"key":"2025030417510723900_r33","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/698313","article-title":"Interleukin 6 and rheumatoid arthritis","volume":"2014","author":"Yoshida","year":"2014","journal-title":"BioMed Res. Int."},{"key":"2025030417510723900_r34","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.7326\/0003-4819-119-11-199312010-00002","article-title":"Hydroxychloroquine compared with placebo in rheumatoid arthritis. A randomized controlled trial","volume":"119","author":"Clark","year":"1993","journal-title":"Ann. Intern. Med."},{"key":"2025030417510723900_r35","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1191\/0961203302lu203ra","article-title":"Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of an Israeli cohort","volume":"11","author":"Molad","year":"2002","journal-title":"Lupus"},{"key":"2025030417510723900_r36","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s12016-010-8243-x","article-title":"Hydroxychloroquine: from malaria to autoimmunity","volume":"42","author":"Ben-Zvi","year":"2012","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"2025030417510723900_r37","doi-asserted-by":"crossref","first-page":"4390","DOI":"10.1016\/j.bmc.2015.06.029","article-title":"Synthesis and evaluation of the anti-nociceptive and anti-inflammatory activity of 4-aminoquinoline derivatives","volume":"23","author":"de Meneses Santos","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"2025030417510723900_r38","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/ncprheum0047","article-title":"Mechanisms of disease: the molecular and cellular basis of joint destruction in rheumatoid arthritis","volume":"1","author":"M\u00fcller-Ladner","year":"2005","journal-title":"Nat. Clin. Pract. Rheumatol."},{"key":"2025030417510723900_r39","doi-asserted-by":"crossref","first-page":"iv52","DOI":"10.1136\/ard.2005.042424","article-title":"Are fibroblasts involved in joint destruction?","volume":"64","author":"Pap","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"2025030417510723900_r40","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2119\/molmed.2010.00138","article-title":"Contribution of neutrophils to acute lung injury","volume":"17","author":"Grommes","year":"2011","journal-title":"Mol. Med."},{"key":"2025030417510723900_r41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0067976","article-title":"Measuring myeloperoxidase activity in biological samples","volume":"8","author":"Pulli","year":"2013","journal-title":"PLoS One"},{"key":"2025030417510723900_r42","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3949\/ccjm.25.2.95","article-title":"Further observations on the use of 4-aminoquinoline compounds in patients with rheumatoid arthritis or related diseases","volume":"25","author":"Scherbel","year":"1958","journal-title":"Cleve. Clin. Q."},{"key":"2025030417510723900_r43","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1186\/ar1917","article-title":"Interleukin-6 and chronic inflammation","volume":"8","author":"Gabay","year":"2006","journal-title":"Arthritis Res. Ther."},{"key":"2025030417510723900_r44","first-page":"149","article-title":"TNF-mediated inflammatory disease","volume-title":"J. Pathol.","author":"Bradley","year":"2008"},{"key":"2025030417510723900_r45","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.brainresrev.2008.12.020","article-title":"Role of interleukin-1beta during pain and inflammation","volume":"60","author":"Ren","year":"2009","journal-title":"Brain Res. Rev."},{"key":"2025030417510723900_r46","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/jlb.56.5.559","article-title":"Essential involvement of interleukin-8 (IL-8) in acute inflammation","volume":"56","author":"Harada","year":"1994","journal-title":"J. Leukoc. Biol."},{"key":"2025030417510723900_r47","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.pharmthera.2013.09.004","article-title":"Targeting interleukin-6 in inflammatory autoimmune diseases and cancers","volume":"141","author":"Yao","year":"2014","journal-title":"Pharmacol. Ther."},{"key":"2025030417510723900_r48","doi-asserted-by":"crossref","first-page":"112","DOI":"10.3349\/ymj.2015.56.1.112","article-title":"The effect of bortezomib on expression of inflammatory cytokines and survival in a murine sepsis model induced by cecal ligation and puncture","volume":"56","author":"Han","year":"2015","journal-title":"Yonsei Med. J."},{"key":"2025030417510723900_r49","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1038\/mt.2010.53","article-title":"Detrimental effect of the proteasome inhibitor, bortezomib in bacterial superantigen- and lipopolysaccharide-induced systemic inflammation","volume":"18","author":"Tilahun","year":"2010","journal-title":"Mol. Ther."},{"key":"2025030417510723900_r50","first-page":"692","article-title":"Comparison of hydroxychloroquine and chloroquine use and the development of retinal toxicity","volume":"12","author":"Finbloom","year":"1985","journal-title":"J. Rheumatol."},{"key":"2025030417510723900_r51","first-page":"R1058","article-title":"Chloroquine inhibits proinflammatory cytokine release into human whole blood","volume":"274","author":"Karres","year":"1998","journal-title":"Am. J. Physiol."},{"key":"2025030417510723900_r52","article-title":"Biologic disease-modifying antirheumatic drugs","volume-title":"Chronic Illnesses II.","author":"Burke","year":"2014"},{"key":"2025030417510723900_r53","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1177\/1759720X10378372","article-title":"The role of interleukin 6 in the pathophysiology of rheumatoid arthritis","volume":"2","author":"Srirangan","year":"2010","journal-title":"Ther. Adv. Musculoskelet. Dis."}],"container-title":["The Journal of Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/204\/4\/788\/61360348\/ji1900531.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/204\/4\/788\/61360348\/ji1900531.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T18:19:18Z","timestamp":1741112358000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jimmunol\/article\/204\/4\/788\/7943905"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,2,15]]}},"URL":"https:\/\/doi.org\/10.4049\/jimmunol.1900531","relation":{},"ISSN":["0022-1767","1550-6606"],"issn-type":[{"value":"0022-1767","type":"print"},{"value":"1550-6606","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,2]]},"published":{"date-parts":[[2020,2]]}}}